Healthcare / BiotechnologyParis
$0.81
-0.01 (-1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-37.4M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$223M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-47.9%
FCF CAGR
—
FCF margin
-7732.2%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $490000.0 · net income $-37.5M · FCF $-37.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $490000.00 | $490000.00 | $307000.00 | $1.4M | $3.5M |
| Net Income | $-37.5M | $-37.5M | $-34.0M | $-22.3M | $-32.8M |
| EBITDA | $-34.9M | $-34.9M | $-31.0M | $-20.6M | $-30.3M |
| EPS | -0.26 | -0.26 | -0.29 | -0.22 | -0.33 |
| Operating Margin | -6938.4% | -6938.4% | -11624.1% | -1977.6% | -857.4% |
| Net Margin | -7658.0% | -7658.0% | -11065.5% | -1539.9% | -945.9% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.08 | 0.06 |
| Current Ratio | 9.62 | 9.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-37.9M | $-37.9M | $-26.6M | $-37.4M | $-21.8M |
| Returns | |||||
| ROE | -30.8% | -30.8% | -223.4% | -143.0% | -86.7% |
| Valuation | |||||
| P/B | 0.96 | 0.96 | 5.23 | 8.84 | 4.89 |
| Growth & Yield | |||||
| Revenue Growth | 59.6% | 59.6% | -78.8% | -58.2% | — |
| EPS Growth | 10.3% | 10.3% | -31.8% | 33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.29 → -0.26
Residual
-14.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.